Press Releases

Press Releases

July 24, 2018
BeiGene Initiates Phase 3 Pivotal Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer in China BEIJING, China, and CAMBRIDGE, Mass., July 24, 2018 (GLOBE NEWSWIRE) --  BeiGene, Ltd.
July 3, 2018
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) CAMBRIDGE, Mass., and BEIJING, China, July 03, 2018 (GLOBE NEWSWIRE) --  BeiGene, Ltd.  (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and
June 5, 2018
CAMBRIDGE, Mass. and BEIJING, China , June 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the